Europe Antimicrobial Susceptibility Testing Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 42
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 45
2 MARKET SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT TYPE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET APPLICATION COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
5 MARKET OVERVIEW 65
5.1 DRIVERS 67
5.1.1 RISE IN EPIDEMIC AND PANDEMIC OUTBREAK 67
5.1.2 INCREASING PREVALENCE OF MULTI-DRUG RESISTANCE ORGANISM 67
5.1.3 AVAILABILITY OF ADVANCED ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS 68
5.1.4 HIGH PREVALENCE OF INFECTIOUS DISEASES 68
5.1.5 DEVELOPMENT OF NEW GENOMIC IDENTIFICATION METHODS 69
5.2 RESTRAINTS 69
5.2.1 STRINGENT GOVERNMENT REGULATIONS 69
5.2.2 HIGH COSTS OF AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS 69
5.2.3 SHORTAGE OF SKILLED PERSONNEL 70

5.3 OPPORTUNITIES 70
5.3.1 INCREASING PRODUCT LAUNCHES 70
5.3.2 INCREASE IN FUNDING 71
5.3.3 STRATEGIC DECISIONS TAKEN BY KEY MARKET PLAYERS 71
5.4 CHALLENGES 72
5.4.1 EMERGENCE OF LOCAL PLAYERS 72
5.4.2 DELAYS BETWEEN CLINICAL BREAKPOINT AND ITS CLEARANCE 72
5.4.3 LACK OF CLINICAL DATA FROM FDA 73
6 IMPACT OF COVID-19 ON EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 74
6.1 IMPACT ON PRICE 74
6.2 IMPACT ON DEMAND 74
6.3 IMPACT ON SUPPLY 74
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19 75
6.5 CONCLUSION: 75
7 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE 76
7.1 OVERVIEW 77
7.2 INSTRUMENTS 80
7.2.1 MANUAL 81
7.2.1.1 MINIATURIZED IDENTIFICATION SYSTEMS 81
7.2.1.2 SUSCEPTIBILITY TESTING DISCS 81
7.2.1.2.1 DODECA DISCS 82
7.2.1.2.1.1 GENERAL PURPOSE 82
7.2.1.2.1.2 GRAM NEGATIVE ORGANISM 82
7.2.1.2.1.3 GRAM POSITIVE ORGANISM 83
7.2.1.2.1.4 PSEUDOMONAS 83
7.2.1.2.1.5 UTI ORGANISMS 83
7.2.1.2.2 HEXA DISCS 83
7.2.1.2.2.1 GRAM NEGATIVE ORGANISMS 84
7.2.1.2.2.2 GRAM POSITIVE ORGANISMS 84
7.2.1.2.2.3 GENERAL PURPOSE 84
7.2.1.2.2.4 ANAEROBIC BACTERIA 84
7.2.1.2.2.5 ANTIFUNGAL 84
7.2.1.2.2.6 OTHERS 84
7.2.1.2.3 ICOSA DISCS 84
7.2.1.2.3.1 GENERAL PURPOSE 85
7.2.1.2.3.2 PSEUDOMONAS 85
7.2.1.2.3.3 UTI ORGANISMS 85

7.2.1.2.4 OCTO DISCS 85
7.2.1.2.4.1 GRAM NEGATIVE ORGANISMS 86
7.2.1.2.4.2 GRAM POSITIVE ORGANISMS 86
7.2.1.2.4.3 UTI ORGANISMS 86
7.2.1.2.4.4 PSEUDOMONAS 86
7.2.1.2.4.5 GENERAL PURPOSE 86
7.2.1.2.4.6 OTHERS 87
7.2.1.2.5 MIC STRIPS 87
7.2.1.2.5.1 COMBINATION ANTIBACTERIAL 87
7.2.1.2.5.2 DUAL ANTIBACTERIAL 87
7.2.1.2.5.3 MULTIPLE ANTIBACTERIAL 87
7.2.1.2.5.4 SINGLE ANTIBACTERIAL 88
7.2.1.2.5.5 ANTIFUNGAL 88
7.2.1.2.5.6 OTHERS 88
7.3 AUTOMATED IDENTIFICATION AND SUSCEPTIBILITY TESTING SYSTEM 88
7.4 CONSUMABLES & ACCESSORIES 88
7.4.1 REAGENTS & BROTHS 89
7.4.2 MEDIA 89
7.4.3 SUSCEPTIBILITY PANELS 89
7.4.4 OTHERS 90
7.5 SERVICES & SOFTWARE 90
8 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHODS 91
8.1 OVERVIEW 92
8.2 DISK DIFFUSION 95
8.3 DILUTION 95
8.4 MASS SPECTROMETRY METHOD 96
8.5 E-TEST 97
8.6 GENEOTYPIC METHODS 97
8.7 RAPID-AST 98
9 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 99
9.1 OVERVIEW 100
9.2 ANTI BACTERIAL TESTING 103
9.3 ANTI FUNGAL TESTING 103
9.4 OTHERS 104

10 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 105
10.1 OVERVIEW 106
10.2 CLINICAL DIAGNOSTICS 109
10.3 DRUG DISCOVERY AND DEVELOPMENT 109
10.4 EPIDEMIOLOGY 110
10.5 OTHERS 111
11 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 112
11.1 OVERVIEW 113
11.2 HOSPITALS 116
11.3 DIAGNOSTIC LABORATORIES 116
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 117
11.5 CONTRACT RESEARCH ORGANIZATIONS 118
11.6 RESEARCH CENTRES AND ACADEMIC INSTITUTES 118
11.7 OTHERS 119
12 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY DISTRIBUTION CHANNEL 120
12.1 OVERVIEW 121
12.2 DIRECT SALES 124
12.3 RETAIL SALES 124
12.4 THIRD PARTY DISTRIBUTOR 125
13 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION 126
13.1 EUROPE 127
13.1.1 GERMANY 137
13.1.2 U.K. 142
13.1.3 FRANCE 147
13.1.4 ITALY 152
13.1.5 SPAIN 157
13.1.6 RUSSIA 162
13.1.7 NETHERLANDS 167
13.1.8 SWITZERLAND 172
13.1.9 BELGIUM 177
13.1.10 TURKEY 182
13.1.11 REST OF EUROPE 187

14 EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY LANDSCAPE 188
14.1 COMPANY SHARE ANALYSIS: EUROPE 188
15 SWOT ANALYSIS 189
16 COMPANY PROFILE 190
16.1 THERMO FISHER SCIENTIFIC INC. 190
16.1.1 COMPANY SNAPSHOT 190
16.1.2 REVENUE ANALYSIS 190
16.1.3 COMPANY SHARE ANALYSIS 191
16.1.4 PRODUCT PORTFOLIO 192
16.1.5 RECENT DEVELOPMENTS 193
16.2 BIOMRIEUX SA 194
16.2.1 COMPANY SNAPSHOT 194
16.2.2 REVENUE ANALYSIS 194
16.2.3 COMPANY SHARE ANALYSIS 195
16.2.4 PRODUCT PORTFOLIO 195
16.2.5 RECENT DEVELOPMENTS 196
16.3 MERCK KGAA 197
16.3.1 COMPANY SNAPSHOT 197
16.3.2 REVENUE ANALYSIS 197
16.3.3 COMPANY SHARE ANALYSIS 198
16.3.4 PRODUCT PORTFOLIO 198
16.3.5 RECENT DEVELOPMENTS 199
16.4 DANAHER 200
16.4.1 COMPANY SNAPSHOT 200
16.4.2 REVENUE ANALYSIS 200
16.4.3 COMPANY SHARE ANALYSIS 201
16.4.4 PRODUCT PORTFOLIO 202
16.4.5 RECENT DEVELOPMENTS 203
16.5 ACCELERATE DIAGNOSTICS, INC. 204
16.5.1 COMPANY SNAPSHOT 204
16.5.2 REVENUE ANALYSIS 204
16.5.3 PRODUCT PORTFOLIO 205
16.5.4 RECENT DEVELOPMENTS 205
16.6 ALIFAX S.R.L. 206
16.6.1 COMPANY SNAPSHOT 206
16.6.2 PRODUCT PORTFOLIO 206
16.6.3 RECENT DEVELOPMENTS 207
16.7 BACTERIOSCAN, INC. 208
16.7.1 COMPANY SNAPSHOT 208
16.7.2 PRODUCT PORTFOLIO 208
16.7.3 RECENT DEVELOPMENTS 209
16.8 BD 210
16.8.1 COMPANY SNAPSHOT 210
16.8.2 REVENUE ANALYSIS 210
16.8.3 PRODUCT PORTFOLIO 211
16.8.4 RECENT DEVELOPMENTS 211
16.9 BIO-RAD LABORATORIES, INC. 212
16.9.1 COMPANY SNAPSHOT 212
16.9.2 REVENUE ANALYSIS 212
16.9.3 COMPANY SHARE ANALYSIS 213
16.9.4 PRODUCT PORTFOLIO 213
16.9.5 RECENT DEVELOPMENTS 214
16.10 CREATIVE DIAGNOSTICS 215
16.10.1 COMPANY SNAPSHOT 215
16.10.2 PRODUCT PORTFOLIO 215
16.10.3 RECENT DEVELOPMENTS 216
16.11 ERBA GROUP 217
16.11.1 COMPANY SNAPSHOT 217
16.11.2 PRODUCT PORTFOLIO 217
16.11.3 RECENT DEVELOPMENTS 218
16.12 GENEFLUIDICS, INC. 219
16.12.1 COMPANY SNAPSHOT 219
16.12.2 PRODUCT PORTFOLIO 219
16.12.3 RECENT DEVELOPMENTS 220
16.13 HIMEDIA LABORATORIES 221
16.13.1 COMPANY SNAPSHOT 221
16.13.2 PRODUCT PORTFOLIO 221
16.13.3 RECENT DEVELOPMENTS 222
16.14 LIOFILCHEM S.R.L. 223
16.14.1 COMPANY SNAPSHOT 223
16.14.2 PRODUCT PORTFOLIO 223
16.14.3 RECENT DEVELOPMENTS 224
16.15 MAST GROUP LTD. 225
16.15.1 COMPANY SNAPSHOT 225
16.15.2 PRODUCT PORTFOLIO 225
16.15.3 RECENT DEVELOPMENTS 226

16.16 MERLIN GESELLSCHAFT FUR MICROBIOLOGISCHE DIAGNOSTIKA MBH 227
16.16.1 COMPANY SNAPSHOT 227
16.16.2 PRODUCT PORTFOLIO 227
16.16.3 RECENT DEVELOPMENTS 228
16.17 NUMEDII, INC. 229
16.17.1 COMPANY SNAPSHOT 229
16.17.2 TECHNOLOGY PORTFOLIO 229
16.17.3 RECENT DEVELOPMENTS 230
16.18 ROSCO DIAGNOSTICA A/S 231
16.18.1 COMPANY SNAPSHOT 231
16.18.2 PRODUCT PORTFOLIO 231
16.18.3 RECENT DEVELOPMENT 231
16.19 SYNBIOSIS 232
16.19.1 COMPANY SNAPSHOT 232
16.19.2 PRODUCT PORTFOLIO 232
16.19.3 RECENT DEVELOPMENTS 233
16.20 ZHUHAI DL BIOTECH CO., LTD 234
16.20.1 COMPANY SNAPSHOT 234
16.20.2 PRODUCT PORTFOLIO 234
16.20.3 RECENT DEVELOPMENT 234
17 QUESTIONNAIRE 235
18 RELATED REPORTS 239